Trevi Therapeutics, Inc.
TRVI Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$12.51
KIRA · Stoqly’s AI analyst, in plain words
- Trevi Therapeutics, Inc. lost $42.8M in fiscal 2025.
- Free cash flow was −$42.1M in fiscal 2025, — of revenue.
Market cap
$2.0B
P/E
—
Revenue
—
Net income
−$42.8M
Free cash flow
−$42.1M
Operating margin
—
Trevi Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$42.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Trevi Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Trevi Therapeutics, Inc.
- CIK
- 0001563880
Trevi Therapeutics, Inc. · TRVI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$33.9M | −$29.2M | −$29.1M | −$47.9M | −$42.8M |
| Diluted EPS | −$1.49 | −$0.45 | −$0.29 | −$0.47 | −$0.32 |
| Cash | |||||
| Cash from operations | −$28.9M | −$28.2M | −$31.7M | −$38.3M | −$42.1M |
| Capital expenditure | — | $0.2M | $0.1M | $0.0M | $0.0M |
| Free cash flow | — | −$28.3M | −$31.8M | −$38.3M | −$42.1M |
| Share count change | 26.5% | 182.6% | 53.4% | 3.0% | 32.1% |
| Debt and strength | |||||
| Cash and short-term investments | $36.8M | $121M | $83.0M | $108M | $188M |
| Shareholders' equity | $17.1M | $107M | $82.5M | $99.6M | $183M |
| Current ratio | 3.0x | 9.2x | 15.0x | 10.4x | 19.7x |
| Interest coverage | −27.0x | −25.7x | −86.8x | −12,881.0x | — |
| Returns and quality | |||||
| Return on equity | −153.0% | −46.8% | −30.6% | −52.6% | −30.2% |
| Return on tangible equity | −198.8% | −27.1% | −35.2% | −48.1% | −23.3% |
| Altman Z'' | −15.9 | 5.9 | 7.4 | 3.6 | 17.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.6M
1 insider
Of sales under plans
100%
$0.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Trevi Therapeutics, Inc. · TRVI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $12.51 a share, the company is worth $2.0B.
Source: SEC EDGAR XBRL filings (CIK 0001563880). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.